Investor Center Home


Corporate Profile
Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders.

More >>

BLCM (Common Stock)
(US Dollar)
Price$7.71
Change Stock is Down 0.2
(%)Volume (2.53%)323,267
ExchangeNASDAQ
Data as of 08/17/17 2:56 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News
DateTitle 
08/08/17Bellicum Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate UpdatePrinter Friendly Version
08/03/17Bellicum Pharmaceuticals Appoints Gregory Naeve as Chief Business OfficerPrinter Friendly Version
08/01/17Bellicum Pharmaceuticals to Report Second Quarter 2017 Financial Results and Host Conference Call and Webcast on August 8, 2017Printer Friendly Version
06/23/17Bellicum Reports Clinical Results of BPX-501 in Pediatric Leukemias at the 22nd Congress of the European Hematology AssociationPrinter Friendly Version
More >>
Upcoming Events
There are currently no events scheduled.
Past Events
08/08/17 5:00 p.m. ET
Q2 2017 Bellicum Pharmaceuticals Earnings Conference Call
Click here for webcast
06/23/17
Bellicum Pharmaceuticals Inc at European Hematology Association Presentation Details

Oral Presentation - Presidential Symposium: “BPX-501 Donor T-Cell Infusion (with Inducible Caspase 9 Suicide Gene) Facilitates HLA Haploidentical Stem Cell Transplant in Children with both Hematological Malignancies and Non-Malignant Conditions”
Session Title: Presidential Symposium
Date: Friday, June 23
Session Time: 3:45 – 4:00 PM CEST
Location Hall A
Abstract Code: S146

Oral Presentation: “Impact of Post-Transplant Infusion of Donor T-Cells Genetically Modified with Inducible Caspase 9 Suicide Gene (BPX-501 Cells) on Children with Leukemia Given Alpha-Beta T-Cell Depleted Haplo-HSCT”
Session Title: Stem cell transplantation – Clinical 1
Session Name: 732.Clinical Allogeneic Transplantation: Results: Predicting Outcome
Date: Saturday, June 24
Session Time: 5:00 – 5:15 PM CEST
Location: Room N103
Abstract Code: S495

Poster Presentation: “The Use of BPX-501 Donor T-Cell Infusion (with Inducible Caspase 9 Suicide Gene) Together with HLA-Haploidentical Stem Cell Transplant to Treat Children with Hemoglobinopathies and Erythroid Disorders”
Session Title: Stem cell transplantation – Clinical 1
Date: Friday, June 23
Time: 5:15 – 6:45 PM CEST
Session Time: Poster Area (Hall 7)

More >>
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources